Meridian Bioscience News
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Blood-PCR ...
Meridian Biosciences' fourth-quarter fiscal 2013 earnings per share missed the Zacks Consensus Estimate by a penny.
Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 GuidanceBusiness Wire Sep 9
Meridian Bioscience, Inc., Cincinnati, Ohio today provided the financial community with guidance regarding the Company’s fiscal 2014 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2014, management expects net sales to be in the range of $203 to $208 million and per share diluted earnings to be between $0.98 and ...
Investors considering a purchase of Meridian Bioscience Inc. stock, but tentative about paying the going market price of $23.06/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Wall Street Transcript Interview with Richard King, the Director, President and CEO of AcelRx Pharmaceuticals, Inc. (ACRX)Aug 16
Meridian Life Science® Successfully Manufactures Influenza Challenge Stock for Immune Targeting SystemsBusiness Wire Jul 30
Meridian Life Science, Inc., of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. , is proud to announce that MLS manufactured an H1N1 influenza A challenge stock for Immune Targeting Systems, Ltd.